Study reveals immunogenicity response of double dose Covishied is higher than Covaxin

Hyderabad, September 11, 2021:

A new study conducted at Chanukya Endocrine Centre in Hyderabad has revealed that people who have taken double dose of Covishied vaccine are having higher immunogenicity response compared to those who have been inoculated with Covaxin.

According to Dr G V Chanukya, lead author of the study, they had taken up this study as a pilot project to ascertain the effectiveness and immunogenicity response by measuring the titer levels of vaccinated people.

As part of their study, the researchers looked into the IgG titer levels or antibody levels of as many as 54 patients and checked the IgG anti-spike neutralizing antibody levels, 10 days after they took the second dose of the vaccine.

“We have taken up this project on a pilot basis to find out which vaccine is giving more immunogenicity response against the deadly Covid disease. In fact earlier studies conducted by the vaccine maker companies have relied on the natural infection to measure the immune response. However, what we are doing is measuring and checking the titer levels by employing two sample t-tests for estimating means of IgG titers of respective vaccines. For Covaxin it was 23.7 and for Covishield it was 126.3, the antibody levels were six times greater for Covishield as compared to Covaxin,” says Dr. Chanukya.

Of the 54 patients deployed for the study, the results of 53 persons were analyzed. Of them 30 patients are male and 23 patients are female. Based on their study, it was realized that as many as 28 patents had titers levels i.e. the concentration levels of antibodies is more than 250 value points and 25 patients had titers less than 250 value points.

The titers were lesser amongst those of higher mean age group at 56-57 years as compared to the previous group with more antibodies whose mean age was 55 years. When compared the efficacy of the two vaccines, the study employed two proportion tests and fund the P value to be statistically significant in Covishield than Covaxin. PharmaBiz